VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

Stock Comparison

Agilent Technologies, Inc. vs Stevanato Group S.p.A.

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Agilent Technologies, Inc.

A · New York Stock Exchange

Market cap (USD)$32.7B
Gross margin (TTM)52.2%
Operating margin (TTM)20.6%
Net margin (TTM)18.3%
SectorHealthcare
IndustryMedical - Diagnostics & Research
CountryUS
Data as of2025-12-22
Moat score
65/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Agilent Technologies, Inc.'s moat claims, evidence, and risks.

View A analysis

Stevanato Group S.p.A.

STVN · New York Stock Exchange

Market cap (USD)$4.9B
Gross margin (TTM)29%
Operating margin (TTM)16.6%
Net margin (TTM)11.8%
SectorHealthcare
IndustryMedical - Instruments & Supplies
CountryIT
Data as of2026-05-27
Moat score
61/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Stevanato Group S.p.A.'s moat claims, evidence, and risks.

View STVN analysis

Comparison highlights

  • Moat score gap: Agilent Technologies, Inc. leads (65 / 100 vs 61 / 100 for Stevanato Group S.p.A.).
  • Segment focus: Agilent Technologies, Inc. has 3 segments (41.9% in Agilent CrossLab); Stevanato Group S.p.A. has 3 segments (47% in High-Value Solutions).
  • Primary market structure: Competitive vs Oligopoly. Pricing power: Strong vs Strong.
  • Moat breadth: Agilent Technologies, Inc. has 5 moat types across 2 domains; Stevanato Group S.p.A. has 8 across 3.

Primary market context

Agilent Technologies, Inc.

Agilent CrossLab

Market

Laboratory services, compliance/maintenance, consumables and lab informatics across the lab workflow

Geography

Global

Customer

B2B (installed base labs across pharma, diagnostics, academia and applied markets)

Role

Aftermarket services + consumables + informatics

Revenue share

41.9%

Stevanato Group S.p.A.

High-Value Solutions

Market

High-value primary packaging and integrated solutions for injectable drugs

Geography

Global

Customer

Pharmaceutical, biotechnology, and life sciences companies; fill-finish CMOs

Role

Primary packaging/component manufacturer (ready-to-use), plus supporting services

Revenue share

47%

Side-by-side metrics

Agilent Technologies, Inc.
Stevanato Group S.p.A.
Ticker / Exchange
A - New York Stock Exchange
STVN - New York Stock Exchange
Market cap (USD)
$32.7B
$4.9B
Gross margin (TTM)
52.2%
29%
Operating margin (TTM)
20.6%
16.6%
Net margin (TTM)
18.3%
11.8%
Sector
Healthcare
Healthcare
Industry
Medical - Diagnostics & Research
Medical - Instruments & Supplies
HQ country
US
IT
Primary segment
Agilent CrossLab
High-Value Solutions
Market structure
Competitive
Oligopoly
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
Strong
Strong
Moat score
65 / 100
61 / 100
Moat domains
Demand, Supply
Demand, Supply, Network
Last update
2025-12-22
2026-05-27

Moat coverage

Shared moat types

Design In QualificationBrand TrustService Field Network

Agilent Technologies, Inc. strengths

Installed Base ConsumablesData Workflow Lockin

Stevanato Group S.p.A. strengths

Capex Knowhow ScaleDe Facto StandardLong Term ContractsOperational ExcellenceScope Economies

Segment mix

Agilent Technologies, Inc. segments

Full profile >

Life Sciences and Diagnostics Markets

Oligopoly

39.2%

Agilent CrossLab

Competitive

41.9%

Applied Markets

Oligopoly

18.9%

Stevanato Group S.p.A. segments

Full profile >

High-Value Solutions

Oligopoly

47%

Other Containment and Delivery Solutions

Competitive

44%

Engineering

Competitive

9%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.